.jpeg)
Pertuzumab alone
Pertuzumab (Pertuzumab) is a HER2 dimerization inhibitor that exhibits mechanistic advantages that are different from trastuzumab. One trial showed that pertuzumab had low clinical efficacy when used alone, with all 29 patients who received pertuzumab monotherapy experiencing disease progression, with an objective response rate (ORR) and clinical benefit rate (CBR) of 3.4% and 10.3%, respectively. After adding trastuzumab, the objective response rate and clinical benefit rate were 17.6% and 41.2%, respectively. The progression-free survival of the combination therapy was longer than that of pertuzumab alone (17.4 weeks and 7.1 weeks, respectively). Pertuzumab and trastuzumab combination therapy was more effective than monotherapy and was well tolerated with minimal cardiac dysfunction.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
